Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
Go back to Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways| CYCLACEL PHARMA (NASDAQ: CYCC) | Delayed: 6.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.37 | 52 Week High | $9.72 | |||
| Open | $6.37 | 52 Week Low | $0.30 | |||
| Day High | $6.37 | P/E | N/A | |||
| Day Low | $6.37 | EPS | $-2.02 | |||
| Volume | 138,535 | |||||
| Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (NASDAQ: CYCCP) | Delayed: 5.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.05 | 52 Week High | $11.29 | |||
| Open | $5.05 | 52 Week Low | $3.60 | |||
| Day High | $5.05 | P/E | N/A | |||
| Day Low | $5.05 | EPS | $0.00 | |||
| Volume | 235 | |||||
